Pfizer
Corporate Bias Rating
Expand Summary
Risk Level:
Summary:
Pfizer is High Risk. The company yields to political activism in shaping corporate governance, potentially alienating consumers, dividing employees, and harming shareholders. The company implements race and identity-based policies that replace merit, excellence, and integrity with preferential treatment and outcomes. Pfizer embraces corporate initiatives that redirect its central focus from business goals to partisan policies and divisive issues. This approach fails to safeguard free exercise, free speech, and free enterprise.
View Full Corporate Bias Ratings ReportBoard Bias
Expand Summary
CEO of Pfizer
Albert Bourla DVM Ph.D.
Summary:
Headquartered in New York, Washington D.C., Pfizer is a member of the Fortune 250 operating in the Pharmaceuticals Biotechnology and Life Sciences industry. Albert Bourla DVM Ph.D. serves as CEO/President and Chairman, leading the company’s C-suite executive team and the board of directors. Amongst these teams, the collective leadership is responsible for $269,500 to Republican causes and $1,524,244 to Democratic causes. Under their tenure, Pfizer currently holds a 'High Risk' risk rating.
View Full Board Bias ReportPolitical Contributions of Leadership:
$269,500
$1,524,244
Republican
Democrat
China Risk Database
Expand Summary
Number of Facilities: 3
Total Estimated Sanctions (3-year Avg.)
$407,386,695
Average Annual Revenue
Global
$60,935,333,333
China Revenue
1.38%
$838,000,000
Annual Average of Total Assets
Global
$170,285,333,333
China Assets
1.82%
$3,103,020,384
Shareholder Proposals
Expand Summary
| Date | ESG Category | Proponent | Summary of Resolution | Mgmt Rec | Total Vote % in Favor |
|---|---|---|---|---|---|
| 4/25/24 | The New York City Carpenters Pension Fund | Amend Director Resignation Processes | Against | N/A | |
| 4/25/24 | National Center for Public Policy Research | Publish a Report on Corporate Contributions | Against | N/A | |
| 4/25/24 | Kenneth Steiner | Independent Board Chairman | Against | N/A | |
| 4/25/24 | Tara Health Foundation | Political Contributions Congruency Report | Against | N/A | |
| 4/27/23 | Governance | Kenneth Steiner | Independent Board Chair | Against | 34.52% |
| 4/27/23 | Social | Trinity Health | Report on Impact of Extended Patent Exclusivities on Product Access | Against | 29.67% |
| 4/27/23 | Governance | Tara Health Foundation | Report on Congruency of Political Contributions | Against | 13.88% |
| 4/27/23 | Social | Oxfam America | Feasibility Report for Transfer of Intellectual Properties to Potential COVID-19 vaccine manufacturers | Against | 11.99% |
| 4/27/23 | Governance | John Chevedden | Ratification of Termination Pay | Against | 9.90% |
| 4/28/22 | Governance | Sisters of St. Francis | Report on Board Oversight of Risks Related to Anticompetitive Practices | Against | 30.45% |
| 4/28/22 | Governance | John Chevedden | Amend Proxy Access Right | Against | 28.98% |
| 4/28/22 | Social | Oxfam America, Inc. | Report on Feasibility of Technology Transfer to Boost COVID-19 Vaccine Production | Against | 27.37% |
| 4/28/22 | Social | National Center for Public Policy Research | Report on Congruency of Political Election Expenditures with Company Values and Policies | Against | 10.41% |
| 4/28/22 | Social | The Shareholder Commons | Report on Public Health Costs of Limited Sharing of Vaccine Technology | Against | 8.71% |
In the News
Expand Summary
Pfizer
Pfizer